Peiwen Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peiwen Chen has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Wen-Hao Hsu
UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, USA
37 shared publications- Fatima Khan
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
33 shared publications - Denise J. Spring
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
31 shared publications - Ronald Anthony DePinho
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
31 shared publications - Maciej S. Lesniak
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, USA
30 shared publications - Amy B. Heimberger
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University , Chicago, Illinois
24 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (9) , 1387-1405
Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells
Glioblastoma (GBM) is a highly aggressive and lethal form of brain tumor that resists immunotherapy. Here we show that neuropeptide galanin (GAL) drives immunosuppression and immunotherapy resistance in GBM. Mechanistically, GBM cell-secreted GAL interacts with its receptor GALR3 on monocytic myeloid-derived suppressor cells (mMDSCs), triggering USP51-mediated deubiquitination of estrogen receptor-α, thereby engaging membrane-bound O -acyltransferase domain-containing 1 signaling. This signaling cascade, in turn, promotes the infiltration of immunosuppressive mMDSCs and confers ferroptosis resistance to them in the tumor microenvironment. Targeting mMDSCs through GALR3 inhibition and ferroptosis induction impairs tumor progression and activates antitumor immunity in GBM mouse models. Remarkably, combining this approach with anti-PD1 therapy achieves durable and complete tumor regression in approximately 60% of tumor-bearing mice. Our study elucidates the molecular mechanism underlying GBM immunosuppression and highlights a promising therapeutic strategy to enhance GBM response to immunotherapy.
- 25 August 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (9) , 1387-1405
Open AccessGalanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells
Glioblastoma (GBM) is a highly aggressive and lethal form of brain tumor that resists immunotherapy. Here we show that neuropeptide galanin (GAL) drives immunosuppression and immunotherapy resistance in GBM. Mechanistically, GBM cell-secreted GAL interacts with its receptor GALR3 on monocytic myeloid-derived suppressor cells (mMDSCs), triggering USP51-mediated deubiquitination of estrogen receptor-α, thereby engaging membrane-bound O -acyltransferase domain-containing 1 signaling. This signaling cascade, in turn, promotes the infiltration of immunosuppressive mMDSCs and confers ferroptosis resistance to them in the tumor microenvironment. Targeting mMDSCs through GALR3 inhibition and ferroptosis induction impairs tumor progression and activates antitumor immunity in GBM mouse models. Remarkably, combining this approach with anti-PD1 therapy achieves durable and complete tumor regression in approximately 60% of tumor-bearing mice. Our study elucidates the molecular mechanism underlying GBM immunosuppression and highlights a promising therapeutic strategy to enhance GBM response to immunotherapy.
- Open Access
- 17 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Symbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by extensive crosstalk between glioblastoma stem cells (GSCs) and immunosuppressive microglia, with our previous work identifying CLOCK and TFPI2 as key regulators of this interaction. Here, we uncover a ‘symbiotic exclusivity’ pattern between CLOCK and TFPI2, showing that, despite mutually exclusive amplifications, they sustain symbiotic regulatory interactions in GBM. The CLOCK-BMAL1 complex transcriptionally upregulates TFPI2, while TFPI2-driven hypoxia inducible factor 1 α (HIF-1α) signaling activates nuclear factor k B (NF-kB) P65 to upregulate the CLOCK-BMAL1 complex, creating a positive feedback loop to promote stemness, immunosuppression, and tumor progression. Disrupting the CLOCK-TFPI2 interplay through dual inhibition of their downstream effectors reduces GSC stemness and immunosuppressive microglia, activates antitumor immunity, and synergizes with anti-PD1 therapy to achieve complete tumor regression in 50%–62.5% of tumor-bearing mice. This study uncovers a promising therapeutic strategy for a broader subset of patients with GBM with high expression of either CLOCK or TFPI2, and provides a framework for identifying ‘symbiotic exclusivity’ genes in cancer. Scientists discovered two genes that cooperate to help aggressive brain tumors grow and evade immunity. Targeting both pathways boosts immune therapy and shrinks tumors in mice.
- 17 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Open AccessSymbiotic exclusivity between CLOCK and TFPI2 drives stemness and immunosuppression in glioblastoma models
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by extensive crosstalk between glioblastoma stem cells (GSCs) and immunosuppressive microglia, with our previous work identifying CLOCK and TFPI2 as key regulators of this interaction. Here, we uncover a ‘symbiotic exclusivity’ pattern between CLOCK and TFPI2, showing that, despite mutually exclusive amplifications, they sustain symbiotic regulatory interactions in GBM. The CLOCK-BMAL1 complex transcriptionally upregulates TFPI2, while TFPI2-driven hypoxia inducible factor 1 α (HIF-1α) signaling activates nuclear factor k B (NF-kB) P65 to upregulate the CLOCK-BMAL1 complex, creating a positive feedback loop to promote stemness, immunosuppression, and tumor progression. Disrupting the CLOCK-TFPI2 interplay through dual inhibition of their downstream effectors reduces GSC stemness and immunosuppressive microglia, activates antitumor immunity, and synergizes with anti-PD1 therapy to achieve complete tumor regression in 50%–62.5% of tumor-bearing mice. This study uncovers a promising therapeutic strategy for a broader subset of patients with GBM with high expression of either CLOCK or TFPI2, and provides a framework for identifying ‘symbiotic exclusivity’ genes in cancer. Scientists discovered two genes that cooperate to help aggressive brain tumors grow and evade immunity. Targeting both pathways boosts immune therapy and shrinks tumors in mice.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S2 TBK1 inhibition abolishes TAMG-induced breast cancer cell EMT, migration, and invasion.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S2 TBK1 inhibition abolishes TAMG-induced breast cancer cell EMT, migration, and invasion.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Breast cancer brain metastasis (BCBM) is the most common and lethal form of brain tumor, marked by abundant infiltration of tumor-associated microglia (TAMG). TAMG can promote the seeding and growth of metastatic breast cancer cells, highlighting the need to elucidate the molecular mechanisms underlying their function to enable the development of effective strategies to target TAMG in BCBM. In this study, using tumor samples from patients with BCBM and mouse models, and in vitro microglia culture systems, we demonstrated that TANK-binding kinase 1 (TBK1) signaling is enriched and activated in TAMG. TBK1 inhibition in TAMG reduced epithelial–mesenchymal transition, migration, invasion, and proliferation of breast cancer cells. Through integrated analyses of transcriptomic profiles, patient survival data, and secretome dataset, followed by experimental validation, GM-CSF was identified as the key secreted protein mediating TBK1-regulated metastatic behaviors of breast cancer cells. Pharmacologic inhibition of TBK1 in BCBM mouse models reduces BCBM and extends survival. Together, these data indicate that TBK1 signaling in TAMG contributes to BCBM and, along with its downstream effector GM-CSF, represents a promising therapeutic target for this deadly disease.Significance:Enrichment and activation of TBK1 in tumor-associated microglia upregulates GM-CSF to promote metastatic properties of breast cancer cells, highlighting TBK1 inhibition as a potential therapeutic opportunity for treating breast cancer brain metastasis.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Breast cancer brain metastasis (BCBM) is the most common and lethal form of brain tumor, marked by abundant infiltration of tumor-associated microglia (TAMG). TAMG can promote the seeding and growth of metastatic breast cancer cells, highlighting the need to elucidate the molecular mechanisms underlying their function to enable the development of effective strategies to target TAMG in BCBM. In this study, using tumor samples from patients with BCBM and mouse models, and in vitro microglia culture systems, we demonstrated that TANK-binding kinase 1 (TBK1) signaling is enriched and activated in TAMG. TBK1 inhibition in TAMG reduced epithelial–mesenchymal transition, migration, invasion, and proliferation of breast cancer cells. Through integrated analyses of transcriptomic profiles, patient survival data, and secretome dataset, followed by experimental validation, GM-CSF was identified as the key secreted protein mediating TBK1-regulated metastatic behaviors of breast cancer cells. Pharmacologic inhibition of TBK1 in BCBM mouse models reduces BCBM and extends survival. Together, these data indicate that TBK1 signaling in TAMG contributes to BCBM and, along with its downstream effector GM-CSF, represents a promising therapeutic target for this deadly disease.Significance:Enrichment and activation of TBK1 in tumor-associated microglia upregulates GM-CSF to promote metastatic properties of breast cancer cells, highlighting TBK1 inhibition as a potential therapeutic opportunity for treating breast cancer brain metastasis.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S1 The expression of TBK1 signature in distinct cell types of BCBM tumors.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S1 The expression of TBK1 signature in distinct cell types of BCBM tumors.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S4 Inhibition of TBK1 in breast cancer cells does not affect their proliferation, apoptosis, and EMT.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S4 Inhibition of TBK1 in breast cancer cells does not affect their proliferation, apoptosis, and EMT.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S5 GM-CSF promotes breast cancer cell EMT, migration, invasion, and proliferation via its receptor CSF2RA.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S5 GM-CSF promotes breast cancer cell EMT, migration, invasion, and proliferation via its receptor CSF2RA.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S3 TBK1 inhibition in TAMG reduces breast cancer cell proliferation but does not affect apoptosis.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Fig. S3 TBK1 inhibition in TAMG reduces breast cancer cell proliferation but does not affect apoptosis.
- Open Access
- 25 September 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (10) , 116342
Neuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma
- 25 September 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (10) , 116342
Open AccessNeuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma
- 18 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (1) , 12-21
Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Breast cancer brain metastasis (BCBM) is the most common and lethal form of brain tumor, marked by abundant infiltration of tumor-associated microglia (TAMG). TAMG can promote the seeding and growth of metastatic breast cancer cells, highlighting the need to elucidate the molecular mechanisms underlying their function to enable the development of effective strategies to target TAMG in BCBM. In this study, using tumor samples from patients with BCBM and mouse models, and in vitro microglia culture systems, we demonstrated that TANK-binding kinase 1 (TBK1) signaling is enriched and activated in TAMG. TBK1 inhibition in TAMG reduced epithelial–mesenchymal transition, migration, invasion, and proliferation of breast cancer cells. Through integrated analyses of transcriptomic profiles, patient survival data, and secretome dataset, followed by experimental validation, GM-CSF was identified as the key secreted protein mediating TBK1-regulated metastatic behaviors of breast cancer cells. Pharmacologic inhibition of TBK1 in BCBM mouse models reduces BCBM and extends survival. Together, these data indicate that TBK1 signaling in TAMG contributes to BCBM and, along with its downstream effector GM-CSF, represents a promising therapeutic target for this deadly disease. Significance: Enrichment and activation of TBK1 in tumor-associated microglia upregulates GM-CSF to promote metastatic properties of breast cancer cells, highlighting TBK1 inhibition as a potential therapeutic opportunity for treating breast cancer brain metastasis.
- 18 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (1) , 12-21
Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis
Breast cancer brain metastasis (BCBM) is the most common and lethal form of brain tumor, marked by abundant infiltration of tumor-associated microglia (TAMG). TAMG can promote the seeding and growth of metastatic breast cancer cells, highlighting the need to elucidate the molecular mechanisms underlying their function to enable the development of effective strategies to target TAMG in BCBM. In this study, using tumor samples from patients with BCBM and mouse models, and in vitro microglia culture systems, we demonstrated that TANK-binding kinase 1 (TBK1) signaling is enriched and activated in TAMG. TBK1 inhibition in TAMG reduced epithelial–mesenchymal transition, migration, invasion, and proliferation of breast cancer cells. Through integrated analyses of transcriptomic profiles, patient survival data, and secretome dataset, followed by experimental validation, GM-CSF was identified as the key secreted protein mediating TBK1-regulated metastatic behaviors of breast cancer cells. Pharmacologic inhibition of TBK1 in BCBM mouse models reduces BCBM and extends survival. Together, these data indicate that TBK1 signaling in TAMG contributes to BCBM and, along with its downstream effector GM-CSF, represents a promising therapeutic target for this deadly disease. Significance: Enrichment and activation of TBK1 in tumor-associated microglia upregulates GM-CSF to promote metastatic properties of breast cancer cells, highlighting TBK1 inhibition as a potential therapeutic opportunity for treating breast cancer brain metastasis.